Sandlerresearch.org

Diabetic Nephropathy Market 2014 - 2018 Global Report

Sandlerresearch.org adds Global Diabetic Nephropathy Market 2014-2018 market research report in its store.

 
Repost This

Dallas, TX -- (SBWIRE) -- 03/20/2014 -- Diabetic nephropathy is a disease of the kidney glomerulus, which is caused by high blood sugar. When diabetes damages kidneys, which contain millions of tiny blood vessel clusters (glomeruli) that filter waste from the blood, this results in diabetic nephropathy, which is also known as diabetic kidney disease. Severe damage can lead to kidney failure or irreversible ESRD, requiring dialysis or a kidney transplant. Hypertension, or high blood pressure, is a complication of diabetes that is believed to contribute most directly to diabetic nephropathy. Treatment to limit progression of diabetic nephropathy involves glycemic control and blood pressure control.

Analysts forecast the Global Diabetic Nephropathy market will grow at a CAGR of 5.19 percent over the period 2013-2018.

Covered in this Report
This report covers the present scenario and the growth prospects of the Global Diabetic Nephropathy market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various diabetic nephropathy drugs available in the market.

The Global Diabetic Nephropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Nephropathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Buy a copy of report @ http://www.sandlerresearch.org/purchase?rname=15825.

Key Regions
- Americas
- EMEA
- APAC

Key Vendors
- Merck & Co. Inc.
- Mitsubishi Tanabe Pharma Corp.
- Novartis AG
- Sanofi S.A.

Other Prominent Vendors
- AbbVie Inc.
- Ampio Pharmaceuticals Inc.
- Astellas Pharma Inc.
- Bayer AG
- ChemoCentryx Inc.
- Eli Lilly and Co.
- GenKyoTex S.A.
- Glycadia Pharmaceuticals Inc.
- IMMD Inc.
- Mesoblast Ltd.
- NephroGenex Inc.
- Novo Nordisk A/S
- NOXXON Pharma AG
- OncoImmune Inc.
- Pfizer Inc.
- PhytoHealth Corp.
- Questcor Pharmaceuticals Inc.
- Reata Pharmaceuticals Inc.

Key Market Driver
- Increase in Prevalence of Diabetes.
- For a full, detailed list, view our report.

Key Market Challenge
- Increasing Number of Patent Expirations.
- For a full, detailed list, view our report.

Key Market Trend
- Increase in Awareness of Diabetic Nephropathy Drugs.
- For a full, detailed list, view our report.

Key Questions Answered in this Report
- What will the market size be in 2018 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors